663600-00-8

Basic information

• Product Name: Oxirane, 2-methyl-2-[(1R)-1-(phenylmethoxy)-3-butenyl]-, (2S)-
• CAS NO: 663600-00-8
• Molecular Formula: C14H18O2
• Molecular Weight: 218.296
• Mol File: 663600-00-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Oxirane, 2-methyl-2-[(1R)-1-(phenylmethoxy)-3-butenyl]-, (2S)-(CAS DataBase Reference)
• NIST Chemistry Reference: Oxirane, 2-methyl-2-[(1R)-1-(phenylmethoxy)-3-butenyl]-, (2S)-(663600-00-8)
• EPA Substance Registry System: Oxirane, 2-methyl-2-[(1R)-1-(phenylmethoxy)-3-butenyl]-, (2S)-(663600-00-8)

Safety Data

• Hazardous Substances Data: 663600-00-8(Hazardous Substances Data)

Upstream product

• 17123-60-3 2-methylhexa-1,5-dien-3-ol 
• 100-39-0 benzyl bromide 
• 663599-88-0 (R)-1-((S)-2-Methyl-oxiranyl)-but-3-en-1-ol 

Downstream Products

• 663599-87-9 C₁₈H₂₆O₂ 
• 663599-90-4 (S)-3-{(R)-3-Benzyloxy-2-[(S)-1-((R)-1-benzyloxy-but-3-enyl)-1,4-dimethyl-pent-3-enyloxy]-propionyl}-4-isopropyl-oxazolidin-2-one 
• 663599-96-0 (2R,7R,8S)-7-Benzyloxy-2-benzyloxymethyl-8-[1,3]dithian-2-ylmethyl-8-methyl-oxocan-3-ol 
• 663599-94-8 1-((2S,3R,8R)-3-Benzyloxy-8-benzyloxymethyl-7-hydroxy-2-methyl-oxocan-2-yl)-3-methyl-butane-2,3-diol 
• 663599-84-6 (R)-5-Benzyloxy-4-[(1S,2R)-2-benzyloxy-1-(3,3-dimethyl-oxiranylmethyl)-1-methyl-pent-4-enyloxy]-pent-1-en-3-ol 
• 663599-91-5 (R)-5-Benzyloxy-4-[(S)-1-((R)-1-benzyloxy-but-3-enyl)-1,4-dimethyl-pent-3-enyloxy]-pent-1-en-3-ol 
• 663599-86-8 (S)-3-{2-[(S)-1-((R)-1-Benzyloxy-but-3-enyl)-1,4-dimethyl-pent-3-enyloxy]-acetyl}-4-isopropyl-oxazolidin-2-one 
• 663599-85-7 (S)-3-Benzyloxy-2-[(S)-1-((R)-1-benzyloxy-but-3-enyl)-1,4-dimethyl-pent-3-enyloxy]-propan-1-ol 
• 663599-95-9 ((2S,3R,8R)-3-Benzyloxy-8-benzyloxymethyl-7-hydroxy-2-methyl-oxocan-2-yl)-acetaldehyde 

Relevant articles and documents

Enantioselective total synthesis of brevetoxin A: Unified strategy for the B, E, G, and J subunits

Brevetoxin A is a decacyclic ladder toxin that possesses 5-, 6-, 7-, 8-, and 9-membered oxacycles, as well as 22 tetrahedral stereocenters. Herein, we describe a unified approach to the B, E, G, and J rings based upon a ring-closing metathesis strategy from the corresponding dienes. The enolate technologies developed in our laboratory allowed access to the precursor acyclic dienes for the B, E, and G medium-ring ethers. The strategies developed for the syntheses of these four monocycles ultimately provided multigram quantities of each of the rings, supporting our efforts toward the completion of a convergent synthesis of brevetoxin A.